Endometrial clear cell adenocarcinoma Trials in Providence, United States
Conditions / Endometrial clear cell adenocarcinoma / Providence, United States
Endometrial clear cell adenocarcinoma has been the subject of sustained clinical investigation across multiple research sites.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING | — |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | TERMINATED | PHASE1/PHASE2 |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | UNKNOWN | PHASE2/PHASE3 |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00942357 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | UNKNOWN | PHASE3 |
| NCT00807768 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | UNKNOWN | PHASE3 |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | TERMINATED | PHASE2 |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | RECRUITING | — |